PDX474.7, one of the selected models, was the most resistant of the whole cohort and displayed a BRCA2 mutation, whereas the other one, PDX252, was a BRCA1 mutant, where olaparib slows down tumor growth without achieving disease control. Here, BRCA2 is linked to neoplasm.